Leonard R. Leo

Array ( [id] => 8733709 [patent_doc_number] => 20130079277 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-03-28 [patent_title] => 'THERAPEUTIC AGENTS COMPRISING ELASTIN-LIKE PEPTIDES' [patent_app_type] => utility [patent_app_number] => 13/445979 [patent_app_country] => US [patent_app_date] => 2012-04-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 32 [patent_figures_cnt] => 32 [patent_no_of_words] => 69025 [patent_no_of_claims] => 43 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13445979 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9299617 [patent_doc_number] => 08647842 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2014-02-11 [patent_title] => 'Methods for producing a fusion protein capable of binding VEGF' [patent_app_type] => utility [patent_app_number] => 13/439889 [patent_app_country] => US [patent_app_date] => 2012-04-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 55 [patent_figures_cnt] => 67 [patent_no_of_words] => 19818 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 72 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13439889 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10516032 [patent_doc_number] => 09243071 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-01-26 [patent_title] => 'Fusion protein for suppression of autoantibodies' [patent_app_type] => utility [patent_app_number] => 14/110287 [patent_app_country] => US [patent_app_date] => 2012-04-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 11 [patent_no_of_words] => 9538 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 34 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14110287 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8845786 [patent_doc_number] => 08454962 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2013-06-04 [patent_title] => 'Alpha-4-beta-7 heterodimer specific antagonist antibody' [patent_app_type] => utility [patent_app_number] => 13/427757 [patent_app_country] => US [patent_app_date] => 2012-03-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26190 [patent_no_of_claims] => 36 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 41 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13427757 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8289335 [patent_doc_number] => 20120177662 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-07-12 [patent_title] => 'ALPHA-4-BETA-7 HETERODIMER SPECIFIC ANTAGONIST ANTIBODY' [patent_app_type] => utility [patent_app_number] => 13/427745 [patent_app_country] => US [patent_app_date] => 2012-03-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26193 [patent_no_of_claims] => 60 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13427745 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9122052 [patent_doc_number] => 20130288974 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-10-31 [patent_title] => 'METHOD FOR AMELIORATING PAIN BY MODIFICATION OF NMDA RECEPTORS THROUGH INHIBITION OF SRC' [patent_app_type] => utility [patent_app_number] => 13/426488 [patent_app_country] => US [patent_app_date] => 2012-03-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 16 [patent_no_of_words] => 15458 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13426488 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9545496 [patent_doc_number] => 20140170144 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-06-19 [patent_title] => 'ANTIBODY RECOGNIZING N-DOMAIN OF MIDKINE' [patent_app_type] => utility [patent_app_number] => 14/004548 [patent_app_country] => US [patent_app_date] => 2012-03-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 17146 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14004548 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10026116 [patent_doc_number] => 09068003 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-06-30 [patent_title] => 'Antibodies that bind to TL1A and methods of treating inflammatory or autoimmune disease comprising administering such antibodies' [patent_app_type] => utility [patent_app_number] => 13/419203 [patent_app_country] => US [patent_app_date] => 2012-03-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 61 [patent_figures_cnt] => 72 [patent_no_of_words] => 56518 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 9 [patent_words_short_claim] => 29 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13419203 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8441488 [patent_doc_number] => 20120258105 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-10-11 [patent_title] => 'METHODS AND COMPOSITIONS TO REGULATE IRON METABOLISM' [patent_app_type] => utility [patent_app_number] => 13/407502 [patent_app_country] => US [patent_app_date] => 2012-02-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 22 [patent_figures_cnt] => 22 [patent_no_of_words] => 21506 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13407502 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8337581 [patent_doc_number] => 20120204281 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-08-09 [patent_title] => 'DRG11-RESPONSIVE (DRAGON) GENE FAMILY' [patent_app_type] => utility [patent_app_number] => 13/407497 [patent_app_country] => US [patent_app_date] => 2012-02-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 22 [patent_figures_cnt] => 22 [patent_no_of_words] => 14686 [patent_no_of_claims] => 28 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13407497 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10594506 [patent_doc_number] => 09315582 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-04-19 [patent_title] => 'Anti-endoglin antibodies and knockin mice expressing novel human/mouse chimeric endoglin' [patent_app_type] => utility [patent_app_number] => 14/001201 [patent_app_country] => US [patent_app_date] => 2012-02-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 19 [patent_figures_cnt] => 17 [patent_no_of_words] => 11619 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 72 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14001201 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9338368 [patent_doc_number] => 20140065150 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-03-06 [patent_title] => 'METHODS AND SYSTEMS FOR TREATING OR PREVENTING PREGNANCY-RELATED HYPERTENSIVE DISORDERS' [patent_app_type] => utility [patent_app_number] => 13/984262 [patent_app_country] => US [patent_app_date] => 2012-02-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 19333 [patent_no_of_claims] => 49 [patent_no_of_ind_claims] => 11 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13984262 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8606085 [patent_doc_number] => 20130011397 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-01-10 [patent_title] => 'Transforming growth factor-beta (TGF-beta) antagonists for use in treating pain' [patent_app_type] => utility [patent_app_number] => 13/337249 [patent_app_country] => US [patent_app_date] => 2011-12-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 13282 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13337249 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8606085 [patent_doc_number] => 20130011397 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-01-10 [patent_title] => 'Transforming growth factor-beta (TGF-beta) antagonists for use in treating pain' [patent_app_type] => utility [patent_app_number] => 13/337249 [patent_app_country] => US [patent_app_date] => 2011-12-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 13282 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13337249 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8346831 [patent_doc_number] => 20120207757 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-08-16 [patent_title] => 'METHODS OF ANTAGONIZING SIGNAL TRANSDUCTION IN SPINAL CORD CELLS' [patent_app_type] => utility [patent_app_number] => 13/332758 [patent_app_country] => US [patent_app_date] => 2011-12-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16751 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13332758 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8663978 [patent_doc_number] => 08377438 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2013-02-19 [patent_title] => 'Methods of antagonizing signal transduction in spinal cord cells' [patent_app_type] => utility [patent_app_number] => 13/331145 [patent_app_country] => US [patent_app_date] => 2011-12-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16038 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 63 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13331145 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8908987 [patent_doc_number] => 08481046 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2013-07-09 [patent_title] => 'VEGF antagonist formulations for intravitreal administration' [patent_app_type] => utility [patent_app_number] => 13/329770 [patent_app_country] => US [patent_app_date] => 2011-12-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5226 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 101 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13329770 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8982080 [patent_doc_number] => 08513194 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2013-08-20 [patent_title] => 'Compositions comprising semaphorins for the treatment of angiogenesis related diseases and methods of selection thereof' [patent_app_type] => utility [patent_app_number] => 13/313063 [patent_app_country] => US [patent_app_date] => 2011-12-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 43 [patent_no_of_words] => 19975 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 50 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13313063 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8128349 [patent_doc_number] => 20120088727 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-04-12 [patent_title] => 'RSPONDINS AS MODULATORS OF ANGIOGENESIS AND VASCULOGENESIS' [patent_app_type] => utility [patent_app_number] => 13/309193 [patent_app_country] => US [patent_app_date] => 2011-12-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 10705 [patent_no_of_claims] => 34 [patent_no_of_ind_claims] => 23 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0088/20120088727.pdf [firstpage_image] =>[orig_patent_app_number] => 13309193 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9482529 [patent_doc_number] => 08728473 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2014-05-20 [patent_title] => 'Methods of preventing or treating pain using anti-NGF antibodies' [patent_app_type] => utility [patent_app_number] => 13/309153 [patent_app_country] => US [patent_app_date] => 2011-12-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 96 [patent_figures_cnt] => 79 [patent_no_of_words] => 75570 [patent_no_of_claims] => 52 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 135 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13309153 [rel_patent_id] =>[rel_patent_doc_number] =>)